The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Application of mechanism-based PKPD model to identify optimal dosing regimens for future development of oraxol.
Gerald J. Fetterly
Consultant or Advisory Role - Kinex Pharmaceuticals
Allison Gaudy
No relevant relationships to disclose
Biao Liu
No relevant relationships to disclose
Patricia D. Meholick
No relevant relationships to disclose
Min-Fun Rudolf Kwan
Employment or Leadership Position - Kinex Pharmaceuticals
Stock Ownership - Kinex Pharmaceuticals
David G. Hangauer
Employment or Leadership Position - Kinex Pharmaceuticals
Stock Ownership - Kinex Pharmaceuticals
Kyung-Mi Park
Employment or Leadership Position - Hanmi
Jeewoong Son
Employment or Leadership Position - Hanmi
Stock Ownership - Hanmi
Yung-Jue Bang
Consultant or Advisory Role - Hanmi
Research Funding - Hanmi